SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi is investigating potential securities-law claims against ARS Pharmaceuticals (NASDAQ: SPRY) and notified investors of an October 5, 2026 deadline to seek lead-plaintiff status in a federal class action. The notice covers investors who purchased or acquired ARS Pharmaceuticals securities between March 9, 2026 and June 24, 2026, creating legal and reputational overhang risk for the company.

Analysis

This is a litigation-advertisement signal rather than an independent fundamental development, so the near-term read-through is primarily technical: incremental retail selling, impaired sentiment, and reduced willingness by new investors to underwrite a biotech catalyst before the complaint’s alleged disclosure failures are understood. For SPRY, the relevant question is whether the underlying issue changes the probability-weighted commercial trajectory of neffy—not the existence of a lawsuit itself. Absent a new FDA, launch, reimbursement, or safety datapoint, litigation alone is unlikely to alter enterprise value materially.

Over the next 1-3 months, the October 5 lead-plaintiff deadline can keep headline risk elevated, particularly if additional firms publicize investigations or an amended complaint introduces specific allegations. The more consequential second-order effect is management distraction during early commercialization: any softness in prescription growth, payer coverage, gross-to-net, or cash-burn guidance could be interpreted through a credibility lens and drive disproportionate multiple compression. Larger allergy/emergency-treatment incumbents such as Viatris (VTRS) and Amphastar (AMPH) have no direct legal benefit, but a delayed SPRY launch could modestly preserve legacy epinephrine economics.

Contrarian view: class-action notices often follow a sharp drawdown and have weak standalone predictive value; shorting solely on this release is low-quality and exposes investors to biotech squeeze risk if prescription or coverage data surprise positively. The thesis turns fundamentally bearish only if SPRY cuts launch expectations, reports materially weaker than expected neffy uptake, or requires incremental financing that shortens its cash runway. Conversely, confirmation of broad payer access and sequential prescription acceleration would likely neutralize the legal overhang faster than the litigation timetable.

Key Decisions for Investors

• No new directional position based solely on the law-firm notice; treat it as a sentiment alert rather than a fundamental catalyst over the next several trading days.
• For existing SPRY longs, reduce position size or hedge through the October 5 deadline if the position depends on near-term multiple expansion; retain only exposure supported by independently verified launch and cash-runway assumptions.
• Establish a watch trigger for SPRY’s next earnings update: a launch-guidance reduction, weaker payer-access disclosure, or cash runway falling below 12 months would support a tactical short or put-spread position for a 1-3 month horizon.
• If SPRY holds above its post-disclosure low while subsequent prescription and reimbursement indicators improve, consider a small event-driven long after the next operating update; risk should be defined below that low, with upside tied to litigation proving non-fundamental and launch execution reasserting itself.